Cognito Therapeutics Announces Spectris™ Treatment Demonstrates Myelin and Synaptic Biomarker Changes in Alzheimer’s Disease
Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced ...
Probe Gold Reports MMI Soil Sampling Results for its Detour Quebec Project
Highlights: Extensive Soil Sampling Program on the Company’s 100%-owned Detour project has successfully identified strong ...